Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Delavirdine mesylate
Drug ID BADD_D00604
Description A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Indications and Usage For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
Marketing Status approved
ATC Code J05AG02
DrugBank ID DB00705
KEGG ID D00895
MeSH ID D020008
PubChem ID 441386
TTD Drug ID D0G6SD
NDC Product Code Not Available
UNII 421105KRQE
Synonyms Delavirdine | Rescriptor | U-90152 | U 90152 | U90152 | U-90152S | U 90152S | U90152S | Delavirdine Mesylate | Mesylate, Delavirdine
Chemical Information
Molecular Formula C23H32N6O6S2
CAS Registry Number 147221-93-0
SMILES CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C.CS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tooth abscess11.01.04.003; 07.09.01.003--Not Available
Toothache07.09.06.001--
Tremor17.01.06.002--
Tuberculosis11.04.01.006--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Fat redistribution14.08.04.002--Not Available
Localised oedema02.05.04.006; 14.05.06.009; 08.01.07.011--
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
Respiratory tract congestion22.02.07.003--Not Available
Affect lability19.04.01.001--Not Available
Body fat disorder14.08.04.012--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Skin mass23.07.04.014--Not Available
Acute kidney injury20.01.03.016--
Anal incontinence17.05.01.021; 07.01.06.029--
Intermenstrual bleeding21.01.01.015--Not Available
The 7th Page    First    Pre   7    Total 7 Pages